

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

ALTIMEO ASSET MANAGEMENT,
Individually and On Behalf of All Others
Similarly Situated,

Plaintiff,

v.

WUXI PHARMATECH (CAYMAN) INC.,
GE LI, EDWARD HU, NING ZHAO,
XIAOZHONG LIU, ZHAOHUI ZHANG,
NEW WUXI LIFE SCIENCE HOLDINGS
LIMITED, NEW WUXI LIFE SCIENCE
LIMITED, WUXI MERGER LIMITED,
G&C PARTNERSHIP L.P., ABG II-WX
LIMITED, BOYU CAPITAL FUND II, L.P.,
HILLHOUSE CAPITAL FUND II, L.P.,
PING AN LIFE INSURANCE COMPANY
OF CHINA. LTD., TEMASEK LIFE
SCIENCES PRIVATE LIMITED, G&C IV
LIMITED, YINFU CAPITAL
MANAGEMENT CO., YUNFENG II WX
LIMITED, SEQUOIA CAPITAL CHINA
GROWTH FUND III, L.P., CONSTANT
CYPRESS LIMITED, and SPDB
INTERNATIONAL HOLDINGS LIMITED,

Defendants.

Case No. 1:19-cv-01654-AJN

CLASS ACTION

**NOTICE OF VOLUNTARY DISMISSAL AS TO DEFENDANTS NEW WUXI LIFE
SCIENCE HOLDINGS LIMITED, NEW WUXI LIFE SCIENCE LIMITED,
AND WUXI MERGER LIMITED**

WHEREAS Defendants New Wuxi Life Science Holdings Limited, New Wuxi Life Science Limited, and Wuxi Merger Limited have not served an answer or motion for summary judgment in the above-captioned action, *Altimeo Asset Management v. WuXi PharmaTech (Cayman)*

Inc., et al., No. 19-cv-01654, brought before the United States District Court for the Southern District of New York;

NOTICE IS HEREBY GIVEN that, pursuant to Federal Rule of Civil Procedure 41(a)(1)(A), Lead Plaintiff Altimeo Asset Management hereby voluntarily dismisses the above-captioned action, without prejudice, solely as to Defendants New Wuxi Life Science Holdings Limited, New Wuxi Life Science Limited, and Wuxi Merger Limited.

Dated: July 26, 2019

POMERANTZ LLP

By: /s/ Michael Grunfeld
Jeremy A. Lieberman
Michael Grunfeld
600 Third Avenue, 20th Floor
New York, New York 10016
Telephone: (212) 661-1100
Fax: (212) 661-8665
Email: jalieberman@pomlaw.com
Email: mgrunfeld@pomlaw.com

*Lead Counsel for Lead Plaintiff Altimeo Asset
Management and the Proposed Class*